Abstract P4-15-01: Cost-effectiveness of pre-implantation genetic diagnosis for BRCA mutation carriers

2017 ◽  
Author(s):  
JH Lipton ◽  
WWL Wong ◽  
E Warner ◽  
EM Greenblatt ◽  
EK Lee ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Brca Mutation ◽  
Genetic Diagnosis ◽  
Mutation Carriers ◽  
Brca Mutation Carriers

scholarly journals Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer

2017 ◽  
Vol 24 (11) ◽  
pp. 3116-3123 ◽  
Author(s):  
Charlotte Gamble ◽  
Laura J. Havrilesky ◽  
Evan R. Myers ◽  
Junzo P. Chino ◽  
Scott Hollenbeck ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cost Effectiveness ◽  
Brca Mutation ◽  
Mutation Carriers ◽  
Brca Mutation Carriers ◽  
History Of ◽  
Risk Reducing

scholarly journals Preimplantation Genetic Testing for BRCA Gene Mutation Carriers: a Cost Effectiveness Analysis

2021 ◽  
Author(s):  
Nadav Michaan ◽  
Moshe Lashno ◽  
Yoni Cohen ◽  
Tamar Safra ◽  
Shira Peleg-Hasson ◽  
...  
Keyword(s):  
Genetic Testing ◽  
Cost Effectiveness ◽  
Embryo Transfer ◽  
Brca Mutation ◽  
Cost Effective ◽  
Preimplantation Genetic Testing ◽  
Mutation Carriers ◽  
Brca Mutation Carriers ◽  
Natural Conception ◽  
Brca Negative

Abstract Background: Gynecologic oncologists should be aware of the option of conception through IVF/PGT-M for families with high BRCA related morbidity or mortality. Our objective was to investigate the cost-effectiveness of preimplantation genetic testing for selection and transfer of BRCA negative embryo in BRCA mutation carriers compared to natural conception.Methods: Cost-effectiveness of two strategies, conception through IVF/PGT-M and BRCA negative embryo transfer versus natural conception with a 50% chance of BRCA positive newborn for BRCA mutation carriers was compared using a Markovian process decision analysis model. Costs of the two strategies were compared using quality adjusted life years (QALYs'). All costs were discounted at 3%. Incremental cost effectiveness ratio (ICER) compared to willingness to pay threshold was used for cost-effectiveness analysis.Results: IVF/ PGT-M is cost-effective with an ICER of 150,219 new Israeli Shekels, per QALY gained (equivalent to 44,480 USD), at a 3% discount rate. Conclusions: IVF/ PGT-M and BRCA negative embryo transfer compared to natural conception among BRCA positive parents is cost effective and may be offered for selected couples with high BRCA mutation related morbidity or mortality. Our results could impact decisions regarding conception among BRCA positive couples and health care providers

Genetic Diagnosis before Surgery has an Impact on Surgical Decision in BRCA Mutation Carriers with Breast Cancer

2017 ◽  
Vol 42 (5) ◽  
pp. 1384-1390
Author(s):  
Sungmin Park ◽  
Jeong Eon Lee ◽  
Jai Min Ryu ◽  
Issac Kim ◽  
Soo Youn Bae ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Brca Mutation ◽  
Genetic Diagnosis ◽  
Surgical Decision ◽  
Mutation Carriers ◽  
Brca Mutation Carriers

scholarly journals Preimplantation genetic testing for BRCA gene mutation carriers: a cost effectiveness analysis

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Nadav Michaan ◽  
Moshe Leshno ◽  
Yoni Cohen ◽  
Tamar Safra ◽  
Shira Peleg-Hasson ◽  
...  
Keyword(s):  
Genetic Testing ◽  
Cost Effectiveness ◽  
Brca Mutation ◽  
Cost Effective ◽  
Preimplantation Genetic Testing ◽  
Effectiveness Analysis ◽  
Mutation Carriers ◽  
Brca Mutation Carriers ◽  
Natural Conception ◽  
Brca Negative

Abstract Background Gynecologic oncologists should be aware of the option of conception through IVF/PGT-M for families with high BRCA related morbidity or mortality. Our objective was to investigate the cost-effectiveness of preimplantation genetic testing for selection and transfer of BRCA negative embryo in BRCA mutation carriers compared to natural conception. Methods Cost-effectiveness of two strategies, conception through IVF/PGT-M and BRCA negative embryo transfer versus natural conception with a 50% chance of BRCA positive newborn for BRCA mutation carriers was compared using a Markovian process decision analysis model. Costs of the two strategies were compared using quality adjusted life years (QALYs’). All costs were discounted at 3%. Incremental cost effectiveness ratio (ICER) compared to willingness to pay threshold was used for cost-effectiveness analysis. Results IVF/ PGT-M is cost-effective with an ICER of 150,219 new Israeli Shekels, per QALY gained (equivalent to 44,480 USD), at a 3% discount rate. Conclusions IVF/ PGT-M and BRCA negative embryo transfer compared to natural conception among BRCA positive parents is cost effective and may be offered for selected couples with high BRCA mutation related morbidity or mortality. Our results could impact decisions regarding conception among BRCA positive couples and health care providers.

Preimplantation genetic diagnosis: What do BRCA mutation carriers think?

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 1526-1526
Author(s):  
Olivia R Khouri ◽  
Deanna Gerber ◽  
Julia Anne Smith ◽  
Leslie R. Boyd
Keyword(s):  
Patient Population ◽  
Brca Mutation ◽  
Genetic Diagnosis ◽  
Cancer Center ◽  
Brca Mutations ◽  
Cost Estimates ◽  
Mutation Carriers ◽  
Number Of Patients ◽  
Wide Range ◽  
Brca Mutation Carriers

1526 Background: The use of pre-implantation genetic diagnosis (PGD) to select against BRCA mutated embryos for in-vitro fertilization (IVF), introduces complex choices for patients with pathogenic BRCA mutations. We sought to describe the uptake of and attitudes toward this technology in this patient population. Methods: We conducted a prospective survey study at a single institution in New York City affiliated with both a Cancer Center and Fertility Center, to assess attitudes and utilization of PGD. Cancer Center staff distributed surveys to patients with known BRCA mutations between April and August 2018. Survey participation was voluntary and anonymous. Survey data were analyzed using descriptive statistics and two-tailed t tests. Results: 80 survey responses were collected. A majority of the patient population identified as Caucasian (87.5%, 70) and Jewish (52.5%, 42). The survey was distributed to all age groups; however 81% (65) were between 26 and 45 years of age. 63.8% (51) had heard of PGD prior to completing the survey, while 36.3% (29) had not. Only 40% of respondents (32) felt sufficiently educated regarding PGD. 35% (28) patients met with an REI, of whom 6.3% (5) utilized IVF with PGD, and 21.3% (17) plan to use IVF with PGD in the future. 11.3% (9) wish they had known about this technology prior to starting a family, 20% (16) would not have used PGD had they known about it prior to childbearing. Reasons respondents were unlikely to pursue PGD included: cost (38.8%, 31), completed childbearing (25%, 20), medical risk (18.8%, 15), and ethical concerns (16.2%, 13). Patients gave cost estimates for PGD ranging from $500 - $120,000. There was no statistically significant correlation between likelihood of pursuing PGD and parity (p = 0.45), religion (p = 0.78), education level (p = 0.13), number of family members affected by BRCA mutations (p = 0.20) or by cancer (p = 0.11). Conclusions: Overall, a small number of patients with pathogenic BRCA mutations utilize PGD. A minority of survey respondents felt adequately educated about PGD. Reported barriers to uptake were varied, and there was a wide range of cost estimates reported. Our results suggest that increased patient education regarding PGD in BRCA mutation carriers is warranted.

scholarly journals BRCA mutation carriers’ perceptions on postmenopausal hormone therapy (HT): An Italian study

2021 ◽  
Author(s):  
Giovanni Grandi ◽  
Valentina Boggio Sola ◽  
Laura Cortesi ◽  
Angela Toss ◽  
Giulia Andrea Giuliani ◽  
...  
Keyword(s):  
Hormone Therapy ◽  
Brca Mutation ◽  
Postmenopausal Hormone Therapy ◽  
Italian Study ◽  
Postmenopausal Hormone ◽  
Mutation Carriers ◽  
Brca Mutation Carriers

Prophylactic Salpingectomy and Delayed Oophorectomy as an Alternative for BRCA Mutation Carriers

2013 ◽  
Vol 68 (6) ◽  
pp. 442-444
Author(s):  
Janice S. Kwon ◽  
Anna Tinker ◽  
Gary Pansegrau ◽  
Jessica McAlpine ◽  
Melissa Housty ◽  
...  
Keyword(s):  
Brca Mutation ◽  
Mutation Carriers ◽  
Prophylactic Salpingectomy ◽  
Brca Mutation Carriers

Bilateral risk‐reducing mastectomy in BRCA mutation carriers: A difficult decision‐making

2019 ◽  
Vol 25 (3) ◽  
pp. 564-565 ◽  
Author(s):  
Gianluca Franceschini ◽  
Riccardo Masetti
Keyword(s):  
Decision Making ◽  
Brca Mutation ◽  
Difficult Decision ◽  
Mutation Carriers ◽  
Brca Mutation Carriers ◽  
Risk Reducing

Use of Mammographic Measurements to Predict Complications After Nipple-Sparing Mastectomy in BRCA Mutation Carriers

2019 ◽  
Vol 27 (2) ◽  
pp. 367-372 ◽  
Author(s):  
Ko Un Park ◽  
Anna Weiss ◽  
Kelly Rosso ◽  
Min Yi ◽  
Kelly Hunt ◽  
...  
Keyword(s):  
Brca Mutation ◽  
Mutation Carriers ◽  
Brca Mutation Carriers ◽  
Nipple Sparing Mastectomy ◽  
Nipple Sparing
Sign in / Sign up

Export Citation Format

Share Document